pCPA Activity Overview
|Under Consideration for Negotiation
|With Letter of Intent: 580
Without agreement: 97
|Negotiations That Were Not Pursued
pCPA Activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement Letters Issued in the last four weeks
|For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
|SIR-Spheres Y-90 resin microspheres
|TheraSphere Y-90 Glass Micropheres
|Boston Scientific Corporation
|Gilead Sciences Canada Inc.
|The treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
|Arcutis Biotherapeutics, Inc.
|For use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to co